ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th

Rhea-AI Summary

ARCA biopharma (Nasdaq: ABIO) announced the participation of COO Thomas Keuer at the Access to Giving Virtual Investor Conference from July 13-15, 2021. The company will present on July 13 at 2:00 PM ET, focusing on precision medicine for cardiovascular diseases. ARCA is developing rNAPc2 for RNA virus-related diseases and Gencaro for atrial fibrillation, both of which have received Fast Track designations from the FDA. The conference aims to promote investor education and advocacy.

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Thomas Keuer, Chief Operating Officer, will present at the Access to Giving Virtual Investor Conference, which is being held virtually July 13-15, 2021.

Access to Giving is a conference themed around investor education and advocacy with 50+ companies presenting, a keynote, three distinctive panels and 1x1 meetings.

ARCA is scheduled to present on Tuesday, July 13, 2021 at 2:00 PM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2744/41973.

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing rNAPc2 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2b clinical testing. ARCA is also developing Gencaro^TM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

About Access to Giving
Access to Giving is the first-of-its-kind virtual investor conference and will be held July 13th - 15th, 2021. Companies will have the opportunity to tell their story and conduct 1x1's with qualified investors for charity. 100% of monies raised through donations for 1x1 meetings will be given to causes that are focused on financial literacy and financial education.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

FAQ

When will ARCA biopharma present at the Access to Giving Virtual Investor Conference?

ARCA biopharma will present on July 13, 2021, at 2:00 PM ET.

What is the focus of ARCA biopharma's presentation at the conference?

The presentation will focus on genetically targeted therapies for cardiovascular diseases.

What are the key products ARCA biopharma is developing?

ARCA biopharma is developing rNAPc2 for RNA virus-related diseases and Gencaro for atrial fibrillation.

What designations have been granted to ARCA biopharma's development programs?

Both the rNAPc2 and Gencaro development programs have received Fast Track designations from the FDA.

What is the purpose of the Access to Giving Virtual Investor Conference?

The conference aims to enhance investor education and advocacy while supporting financial literacy causes.